More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
¡Compre este libro electrónico y obtenga 1 más GRATIS!
Idioma Inglés ● Formato PDF ● Páginas 584 ● ISBN 9781420037937 ● Editorial CRC Press ● Publicado 2002 ● Descargable 3 veces ● Divisa EUR ● ID 5697838 ● Protección de copia Adobe DRM
Requiere lector de ebook con capacidad DRM